Lowering of Mean Pulmonary Arterial Pressure is a Prognostic Marker in Pulmonary Hypertension Patients treated with Subcutaneous Treprostinil

被引：0
|
作者：
Sadushi-Kolici, Roela [1 ]
Shafran, Inbal [2 ]
Skoro-Sajer, Nika [1 ]
Gerges, Christian [1 ]
Lang, Irene [1 ]
机构：
[1] Med Univ Vienna, Internal Med 2, Cardiol, Vienna, Austria
[2] Sheba Med Ctr, Ramat Gan, Israel
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA3968
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Treprostinil (remodulin) for pulmonary arterial hypertension
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1139): : 80 - 82
  • [22] Treprostinil for the treatment of pulmonary arterial hypertension
    Torres, Fernando
    Rubin, Lewis J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (01) : 13 - 25
  • [23] Inhaled treprostinil and pulmonary arterial hypertension
    Nadler, Samuel T.
    Edelman, Jeffrey D.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 1115 - 1124
  • [24] Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension
    Keogh, Anne M.
    Jabbour, Andrew
    Weintraub, Robert
    Brown, Karen
    Hayward, Chris S.
    Macdonald, Peter S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (11): : 1079 - 1083
  • [25] Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension
    Mouratoglou, Sophia Anastasia
    Patsiala, Anthoula
    Feloukidis, Christos
    Karvounis, Haralambos
    Giannakoulas, George
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 187 - 189
  • [26] Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series
    Ackerbauer, Kimberly A.
    Tandon, Rajive
    JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 163 - 166
  • [27] Noninvasive prognostic indicators in treated patients with pulmonary arterial hypertension
    Jasiewicz, M.
    Skiepko, R.
    Knapp, M.
    Jasiewicz, P.
    Szpakowicz, A.
    Sobkowicz, B.
    Bodzenta-Lukaszyk, A.
    Musial, W. J.
    Kaminski, K. A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S228 - S229
  • [28] Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
    Raina, Amresh
    Coons, James C.
    Kanwar, Manreet
    Murali, Srinivas
    Sokos, George
    Benza, Raymond L.
    PULMONARY CIRCULATION, 2013, 3 (01) : 116 - 120
  • [29] Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
    Skoro-Sajer, Nika
    Gerges, Christian
    Balint, Olga Hajnalka
    Kohalmi, Dora
    Kaldararova, Monika
    Simkova, Iveta
    Jakowitsch, Johannes
    Gabriel, Harald
    Baumgartner, Helmut
    Gerges, Mario
    Sadushi-Kolici, Roela
    Celermajer, David S.
    Lang, Irene Marthe
    HEART, 2018, 104 (14) : 1195 - 1199
  • [30] Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension
    Skoro-Sajer, N
    Harja, E
    Bonderman, D
    Rezaie-Majd, S
    Machherndl, S
    Kneussl, M
    Lang, MI
    EUROPEAN HEART JOURNAL, 2003, 24 : 483 - 483
12345